Blood test for small molecules abnormally expressed in pancreatic cancer may be a promising route to early detection of the disease
A blood test for small molecules abnormally expressed in pancreatic cancer may be a promising route to early detection of the disease, researchers at The University of Texas MD Anderson Cancer Center report in the September edition of the journal Cancer Prevention Research.
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention.